A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.
anamorelin
anorexia
body weight
cachexia
gastrointestinal neoplasms
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 Dec 2019
01 Dec 2019
Historique:
received:
18
12
2018
revised:
06
06
2019
accepted:
27
06
2019
pubmed:
16
8
2019
medline:
4
6
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer. Anamorelin (ONO-7643; ANAM) is a novel and selective ghrelin receptor agonist that improves appetite, lean body mass (LBM), body weight, and anorexia. This multicenter, open-label, single-arm study investigated the efficacy and safety of 100 mg anamorelin in 50 Japanese patients with advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer. ANAM was administered once daily over 12 weeks. The primary endpoint was the proportion of patients that maintained or gained LBM over the course of the study. Secondary endpoints included changes in LBM, body weight, quality of life (QoL), and nutritional status biomarkers. The proportion of patients who responded to treatment was 63.3% (95% CI, 48.3%-76.6%), with a least square mean ± SE change in LBM and body weight from baseline of 1.89 ± 0.36 kg and 1.41 ± 0.61 kg, respectively. Appetite-related questions on the QoL questionnaire showed that ANAM improved appetite. Adverse events occurred in 79.6% of patients, and the most common treatment-related adverse events were increased γ-glutamyl transpeptidase (8.2%), diabetes mellitus (6.1%), hyperglycemia (6.1%), and prolonged QRS complex (6.1%). ANAM improved anorexia and patients' nutritional status, resulting in rapid increases in LBM and body weight in patients with advanced gastrointestinal cancer who had cancer cachexia. ANAM treatment was well tolerated over 12 weeks. ANAM is a potential clinically beneficial pharmacotherapeutic option for patients with advanced gastrointestinal cancer who have cancer cachexia.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer cachexia is characterized by weight loss and is associated with increased morbidity and mortality in patients with cancer. Anamorelin (ONO-7643; ANAM) is a novel and selective ghrelin receptor agonist that improves appetite, lean body mass (LBM), body weight, and anorexia.
METHODS
METHODS
This multicenter, open-label, single-arm study investigated the efficacy and safety of 100 mg anamorelin in 50 Japanese patients with advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer. ANAM was administered once daily over 12 weeks. The primary endpoint was the proportion of patients that maintained or gained LBM over the course of the study. Secondary endpoints included changes in LBM, body weight, quality of life (QoL), and nutritional status biomarkers.
RESULTS
RESULTS
The proportion of patients who responded to treatment was 63.3% (95% CI, 48.3%-76.6%), with a least square mean ± SE change in LBM and body weight from baseline of 1.89 ± 0.36 kg and 1.41 ± 0.61 kg, respectively. Appetite-related questions on the QoL questionnaire showed that ANAM improved appetite. Adverse events occurred in 79.6% of patients, and the most common treatment-related adverse events were increased γ-glutamyl transpeptidase (8.2%), diabetes mellitus (6.1%), hyperglycemia (6.1%), and prolonged QRS complex (6.1%).
CONCLUSIONS
CONCLUSIONS
ANAM improved anorexia and patients' nutritional status, resulting in rapid increases in LBM and body weight in patients with advanced gastrointestinal cancer who had cancer cachexia. ANAM treatment was well tolerated over 12 weeks. ANAM is a potential clinically beneficial pharmacotherapeutic option for patients with advanced gastrointestinal cancer who have cancer cachexia.
Identifiants
pubmed: 31415709
doi: 10.1002/cncr.32406
pmc: PMC6900019
doi:
Substances chimiques
Hydrazines
0
Oligopeptides
0
anamorelin
DD5RBA1NKF
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4294-4302Subventions
Organisme : Ono Pharmaceutical Co., Ltd.
Organisme : Ono Pharmaceutical Company Ltd
Informations de copyright
© 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Références
Lancet Oncol. 2017 Feb;18(2):192-201
pubmed: 28094194
J Clin Oncol. 2005 Nov 20;23(33):8500-11
pubmed: 16293879
Support Care Cancer. 2016 Aug;24(8):3473-80
pubmed: 27003901
Scientifica (Cairo). 2013;2013:518909
pubmed: 24381790
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD004310
pubmed: 23543530
Support Care Cancer. 2016 Aug;24(8):3495-505
pubmed: 27005463
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778-788
pubmed: 28614627
Clin Nutr. 2011 Feb;30(1):92-8
pubmed: 20719409
Curr Opin Support Palliat Care. 2018 Dec;12(4):439-444
pubmed: 30138131
Eur J Endocrinol. 2014 Jul;171(1):R21-32
pubmed: 24714083
Support Care Cancer. 2010 Feb;18(2):265-72
pubmed: 19937260
J Clin Diagn Res. 2014 Aug;8(8):MC13-7
pubmed: 25302229
Expert Opin Biol Ther. 2013 Jan;13(1):67-76
pubmed: 23078025
J Clin Invest. 2013 Feb;123(2):611-22
pubmed: 23281394
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3
pubmed: 25384990
Support Care Cancer. 2013 Jan;21(1):129-37
pubmed: 22699302
J Am Med Dir Assoc. 2014 Dec;15(12):866-72
pubmed: 25455531
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):515-519
pubmed: 27239422
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
Peptides. 2011 Nov;32(11):2183-90
pubmed: 21763742
J Cachexia Sarcopenia Muscle. 2015 Jun;6(2):132-43
pubmed: 26136189
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Physiol Rev. 2005 Apr;85(2):495-522
pubmed: 15788704
Lancet Oncol. 2013 Apr;14(4):335-45
pubmed: 23499390
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
J Clin Oncol. 1993 Jan;11(1):152-4
pubmed: 8418227
BMJ. 1997 Nov 8;315(7117):1219-22
pubmed: 9393230
Endocr Rev. 2009 Apr;30(2):152-77
pubmed: 19240267
BMC Geriatr. 2013 Jul 16;13:74
pubmed: 23865675
Oncologist. 2007 May;12(5):594-600
pubmed: 17522248
Support Care Cancer. 2013 Sep;21(9):2409-15
pubmed: 23579947
Diabetes. 2006 Jun;55(6):1813-8
pubmed: 16731847
Cancer. 2018 Feb 1;124(3):606-616
pubmed: 29205286
Br J Pharmacol. 2008 Jun;154(3):557-68
pubmed: 18500379
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):73-83
pubmed: 30334618
Crit Rev Oncol Hematol. 2013 Dec;88(3):625-36
pubmed: 23953794
Lancet Oncol. 2015 Jan;16(1):108-16
pubmed: 25524795
Mol Cell Endocrinol. 2011 Jun 20;340(1):97-105
pubmed: 21354462